These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23603069)

  • 21. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
    Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
    J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Ebbink BJ; Aarsen FK; van Gelder CM; van den Hout JM; Weisglas-Kuperus N; Jaeken J; Lequin MH; Arts WF; van der Ploeg AT
    Neurology; 2012 May; 78(19):1512-8. PubMed ID: 22539577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiopulmonary exercise test to quantify enzyme replacement response in pediatric Pompe disease.
    Bar-Yoseph R; Mandel H; Mainzer G; Gur M; Tal G; Shalloufeh G; Bentur L
    Pediatr Pulmonol; 2018 Mar; 53(3):366-373. PubMed ID: 29356433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
    Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
    Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Dimopoulos F; Papadimas GK; Papadopoulos C; Spengos K; Fatouros I; Kavouras SA; Manta P
    Mol Genet Metab; 2011 Nov; 104(3):279-83. PubMed ID: 21640624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.
    Güngör D; de Vries JM; Hop WC; Reuser AJ; van Doorn PA; van der Ploeg AT; Hagemans ML
    Orphanet J Rare Dis; 2011 Jun; 6():34. PubMed ID: 21631931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.
    Güngör D; Kruijshaar ME; Plug I; Rizopoulos D; Kanters TA; Wens SC; Reuser AJ; van Doorn PA; van der Ploeg AT
    J Inherit Metab Dis; 2016 Mar; 39(2):253-60. PubMed ID: 26531313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
    Orlikowski D; Pellegrini N; Prigent H; Laforêt P; Carlier R; Carlier P; Eymard B; Lofaso F; Annane D
    Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should patients with asymptomatic pompe disease be treated? A nationwide study in France.
    Echaniz-Laguna A; Carlier RY; Laloui K; Carlier P; Salort-Campana E; Pouget J; Laforet P
    Muscle Nerve; 2015 Jun; 51(6):884-9. PubMed ID: 25786784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults.
    Merk T; Wibmer T; Schumann C; Krüger S
    Eur J Neurol; 2009 Feb; 16(2):274-7. PubMed ID: 19138339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.
    Angelini C; Semplicini C; Ravaglia S; Bembi B; Servidei S; Pegoraro E; Moggio M; Filosto M; Sette E; Crescimanno G; Tonin P; Parini R; Morandi L; Marrosu G; Greco G; Musumeci O; Di Iorio G; Siciliano G; Donati MA; Carubbi F; Ermani M; Mongini T; Toscano A;
    J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late-onset Pompe disease.
    Lika A; Andrinopoulou ER; van der Beek NAME; Rizopoulos D; van der Ploeg AT; Kruijshaar ME
    J Inherit Metab Dis; 2023 Jul; 46(4):595-604. PubMed ID: 36966448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.
    van der Beek NA; van Capelle CI; van der Velden-van Etten KI; Hop WC; van den Berg B; Reuser AJ; van Doorn PA; van der Ploeg AT; Stam H
    Mol Genet Metab; 2011; 104(1-2):129-36. PubMed ID: 21763167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exercise training in adults with Pompe disease: the effects on pain, fatigue, and functioning.
    Favejee MM; van den Berg LE; Kruijshaar ME; Wens SC; Praet SF; Pim Pijnappel WW; van Doorn PA; Bussmann JB; van der Ploeg AT
    Arch Phys Med Rehabil; 2015 May; 96(5):817-22. PubMed ID: 25499687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.
    van der Meijden JC; Güngör D; Kruijshaar ME; Muir AD; Broekgaarden HA; van der Ploeg AT
    J Inherit Metab Dis; 2015 May; 38(3):495-503. PubMed ID: 25112389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
    Stepien KM; Hendriksz CJ; Roberts M; Sharma R
    Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.